Childhood & Early Life
Cesar Milstein was born on October 8, 1927 in Bahia Blanca, Argentina to Maxima and Lazaro Milstein, a Jewish Ukrainian immigrant. His mother belonged to a poor immigrant family and was a teacher by profession. He was the second of the three sons born to the couple.
Milstein’s parents were determined to bring up their children with good education. As such, when young Milstein completed his preliminary studies, he was enrolled at the University of Buenos Aires. Milstein though academically average was active in student union affairs and politics.
Upon completing his graduation from the University, Milstein took a year off, travelling through Europe, before returning to Argentina. He resumed his studies with an aim to get a doctoral degree. Under the guidance of Professor Stoppani, the Professor of Biochemistry at the Medical School, Milstein completed his thesis on kinetics studies with the enzyme aldehyde dehydrogenase.
Continue Reading Below
Career
Immediately following his doctoral degree, Milstein was granted a British Council fellowship which led him to join the biochemistry department at Darwin College, University of Cambridge to work under Malcolm Dixon on the project, mechanism of metal activation of the enzyme phosphoglucomutase. While working with Dixon, he joined Frederick Sanger’s group on a short-term Medical Research Council appointment.
After completing his fellowship and collaboration with Sanger’s group, Milstein returned to Argentina in 1961 for a period of two years. Therein, he served as the head of the then newly created Department of Molecular Biology at the National Institute of Microbiology in Buenos Aires. During this time, he extended his study of mechanisms of enzyme action to the enzymes phosphoglyceromutase and alkaline phosphatase.
The 1962 military coup which resulted in the dismissal of Institute’s director Ignacio Pirosky forced Milstein to resign and return to Cambridge.
At Cambridge, Milstein re-joined work with Sanger, who meanwhile had been appointed as the Head of the Division of Protein Chemistry in the newly-formed Laboratory of Molecular Biology of the Medical Research Council. On the suggestion of Sanger, Milstein shifted his focus from enzymology to immunology.
For much of the decade of 1960s and 1970s, Milstein concentrated on the study of antibodies, the protein organisms generated by the immune system to combat and deactivate antigens. His efforts were aimed at analysing myeloma proteins (tumors in cells that produce antibodies), and later DNA and RNA.
Milstein’s research on antibodies was crucial in his early career in immunology as it helped him comprehend the fundamentals of antibodies. He searched for mutations in laboratory cells of myeloma, but faced difficulty finding antigens to combine with their antibodies.
For most of his research years, Milstein concentrated on studying the structure of antibodies and the mechanism by which antibody diversity is generated. It was in 1974 that he struck luck along with Georges Kohler, a postdoctoral fellow at his laboratory, when they produced a hybrid myeloma called hybridoma.
Hybridoma had the capacity to produce antibodies but kept growing like the cancerous cell from which it had originated. The production of monoclonal antibodies from these cells became one of the most important discoveries of decade.
Milstein came up with the Milstein-Kohler paper in 1975 wherein the duo first brought to light the possibility of using monoclonal antibodies for testing antigens. They also predicted the possibility to hybridize antibody-producing cells from different origins, stating that the cells could be produced in massive cultures. The discovery was crucial and led to an enormous expansion in the exploitation of antibodies in science and medicine.
Continue Reading Below
By 1977, Milstein was flooded with requests for samples of monoclonal antibodies, so much so, that he had to search for outside support in the distribution process. This paved way for the earliest wide-scale commercialisation of monoclonal antibodies.
His research work did not end with the discovery of monoclonal antibodies. He furthered his research by making major contributions in the improvement and development of monoclonal antibody technology by focusing on the use of monoclonal antibodies.
Together with Claudio Cuello, Milstein laid the foundation for the use of monoclonal antibodies for the investigation of the pathological pathways in neurological disorders as well as many other diseases. Their work assisted in the use of monoclonal antibodies to enhance the power of immuno-based diagnostic tests.
Milstein predicted the potential of applying recombinant DNA technology to monoclonal antibodies that could result in ligand-binding reagents. He also inspired the development of the field of antibody engineering which lead to safer and more powerful monoclonal antibodies for use as therapeutics.
In 1983, Milstein took up leadership role in the Protein and Nucleic Acid Chemistry Division at the Medical Research Council's laboratory.
Later in his career, Milstein guided and inspired many in the field of antibody. He devoted himself to assist scientists in less developed countries.
Personal Life & Legacy
Cesar Milstein met Celia Prilleltensky, his future wife, while he was studying in the University of Buenos Aires. The two hit it off instantly and married immediately following their graduation in 1953. They spent a year honeymooning, hitch-hicking across Europe before returning to Argentina to resume studies.
Milstein died of a heart condition on March 24, 2002 in Cambridge, England, at the age of 74.
